Clinical Trial Update: Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults [Phase 2]

View source ↗

Summary

Phase 2 safety, tolerability, and immunogenicity data for VAX-24 in older adults have been updated with results posted from the completed study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Pneumococcal Disease
• Pneumococcal Pneumonia

Drugs mentioned

• VAX-24 (24-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Vaxcyte, Inc. | Conditions: Pneumococcal Vaccines | Phase 2 | Status: COMPLETED | Results posted: 2024-04-16